TG Therapeutics announces long-term data on Briumvi published in JAMA Neurology

TG Therapeutics (TGTX) announced the publication of long term/five-year data from the ongoing open-label extension, OLE, of the Phase 3 ULTIMATE I and II studies evaluating Briumvi in adults with relapsing forms of multiple sclerosis. The manuscript was published in JAMA Neurology. The publication presents a comprehensive long-term evaluation of Briumvi and demonstrates durable clinical efficacy, low relapse rates, and a consistent safety profile with up to five years of continuous treatment. Additional details from the publication are included below. Michael Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “Acceptance of these five-year ULTIMATE I & II results in JAMA Neurology represents a major milestone for TG Therapeutics and the MS field. These data underscore not only the durable clinical efficacy and consistent safety of BRIUMVI through extended treatment, but also our commitment to advancing long-term evidence that helps clinicians and patients make informed treatment decisions. We believe these findings support BRIUMVI’s continued role as a valuable option for people living with relapsing MS.”